

## NI Formulary: Chapter 6 Endocrine

Please refer to the full version of the Formulary for further advice and information.

Therapeutic Area	Drug choice
<b>Insulins</b> <b>Rapid (analogue)</b> Immediate with food	<b>Apidra®</b> <b>Humalog® (100,200)</b> <b>Novorapid®</b>
<b>Insulins</b> <b>Short</b> 15 to 30 mins before food	<b>Actrapid®</b> <b>Humulin S®</b> <b>Insuman® Rapid</b>
<b>Insulins</b> <b>Intermediate (Isophane)</b> Same time every day	<b>Insulatard®</b> <b>Humulin I®</b> <b>Insuman® Basal</b>
<b>Insulins</b> <b>Long (analogue)</b> Same time every day	<b>Abasaglar®**</b> <b>Lantus®</b> <b>Levemir®</b> <b>Toujeo®</b> <b>Tresiba® (100,200)</b>
<b>Insulins</b> <b>Biphasic</b> Up to 15 mins before food	<b>Humalog® Mix 50</b> <b>Humalog® Mix 25</b> <b>Novomix® 30</b>
<b>Insulins</b> <b>Biphasic Isophane</b> Up to 30 mins before food	<b>Humulin® M3</b> <b>Insuman® Comb (15, 25, 50)</b>
<b>Biguanides</b>	<span style="color: blue; font-weight: bold;">1</span> <b>Metformin</b> tablets 500mg, 850mg
<b>Sulfonylureas</b>	<span style="color: blue; font-weight: bold;">1</span> <b>Gliclazide</b> tablets 80mg
<b>Dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitors)</b>	<span style="color: blue; font-weight: bold;">1</span> <b>Alogliptin</b> tablets 6.25mg, 12.5mg, 25mg
	<span style="color: blue; font-weight: bold;">1</span> <b>Sitagliptin</b> tablets 25mg, 50mg, 100mg
	<span style="color: green; font-weight: bold;">2</span> <b>Linagliptin</b> tablets 5mg
<b>Glitazones (thiazolidinediones)</b>	<span style="color: blue; font-weight: bold;">1</span> <b>Pioglitazone</b> tablets 15mg, 30mg, 45mg
<b>Sodium-glucose co-transporter 2 (SGLT-2) inhibitors</b>	<span style="color: blue; font-weight: bold;">1</span> <b>Canagliflozin</b> 100mg, 300mg tablets
	<span style="color: blue; font-weight: bold;">1</span> <b>Dapagliflozin</b> 10mg tablets
	<span style="color: blue; font-weight: bold;">1</span> <b>Empagliflozin</b> 10mg, 25mg tablets
<b>GLP-1 mimetic (injectable)</b>	<span style="color: blue; font-weight: bold;">1</span> <b>Liraglutide</b> injection 6mg/mL
	<span style="color: green; font-weight: bold;">2</span> <b>Dulaglutide</b> ▼ 1.5mg/0.5ml solution for injection
<b>Treatment of hypoglycaemia</b>	<span style="color: blue; font-weight: bold;">1</span> <b>Glucose (oral)</b> or <span style="color: blue; font-weight: bold;">1</span> <b>Glucagon</b> 1mg vial (GlucaGen® HypoKit) or <span style="color: blue; font-weight: bold;">1</span> <b>Glucose intravenous infusion 10% 500mL</b>
<b>Hypothyroidism</b>	<span style="color: blue; font-weight: bold;">1</span> <b>Levothyroxine</b> tablets 25micrograms, 50micrograms, 100 micrograms
<b>Hyperthyroidism</b> a) Antithyroid drugs b) Beta-blockers	<span style="color: blue; font-weight: bold;">1</span> <b>Carbimazole</b> tablets 5mg, 20mg <b>To be initiated on specialist advice</b>
	<span style="color: blue; font-weight: bold;">1</span> <b>Propranolol</b> tablets 10mg, 40mg; <b>Propranolol MR</b> capsules 80mg, 160mg

## NI Formulary: Chapter 6 Endocrine

Please refer to the full version of the Formulary for further advice and information.

Therapeutic Area	Drug choice
<b>Hypoparathyroidism</b>	<p>① <b>Alfacalcidol</b> (1<math>\alpha</math>-hydroxycholecalciferol) capsules 250nanograms, 500nanograms, 1microgram; oral drops 2micrograms/mL</p>
<b>Corticosteroids</b> <b>a) Replacement therapy</b>	<p><u>Replacement therapy (mineralocorticoid)</u></p> <p>① <b>Fludrocortisone</b> tablets 100micrograms</p> <p><u>Glucocorticoid therapy</u></p> <p><b>Hydrocortisone</b> tablets 10mg, 20mg</p>
<b>b) Glucocorticoid therapy</b>	<p>① <b>Prednisolone</b> tablets 1mg, 5mg or</p> <p>① <b>Dexamethasone</b> tablets 500micrograms, 2mg; injection 3.8mg/mL; injection 3.3mg/mL or</p> <p>① <b>Hydrocortisone injection (Solu-Cortef®)</b> hydrocortisone (as sodium succinate) 100mg vial with 2mL amp water for injections or</p> <p>① <b>Methylprednisolone</b> tablets 2mg, 4mg, 16mg, 100mg</p> <p>① <b>Methylprednisolone sodium succinate (Solu-Medrone®)</b> vials 40mg, 125mg, 500mg, 1g, 2g</p> <p>① <b>Methylprednisolone acetate (Depo-Medrone®)</b> vials 40mg/mL, 80mg/2mL, 120mg/3mL</p>
<b>Hormone replacement therapy (HRT) for menopausal symptoms</b> <b>a) Women who have not had a hysterectomy</b>	<p>① <u>Sequential combined (oral)</u></p> <p><b>Elleste-Duet®</b> 1mg, 2mg tablets (estradiol and norethisterone) or</p> <p><b>Femoston®</b> 1/10, 2/10 tablets (estradiol and dydrogesterone)</p> <p>① <u>Sequential combined (transdermal)</u></p> <p><b>Evorel® Sequi</b> patches: combination pack of 4 <b>Evorel® 50</b> patches (estradiol 50micrograms/24hours) and 4 <b>Evorel® Conti</b> patches (estradiol 50micrograms/24hours and norethisterone acetate 170micrograms/24hours)</p> <p>② <b>FemSeven Sequi®</b> patches: providing estradiol 50micrograms per 24 hours (phase1); estradiol 50micrograms and levonorgestrel 10micrograms per 24 hours (phase2)</p> <p><u>Continuous combined (oral)</u></p> <p>① <b>Kliovance®</b> tablets (estradiol 1mg and norethisterone 500micrograms)</p> <p>① <b>Kliofem®</b> tablets (estradiol 2mg and norethisterone 1mg)</p> <p>② <b>Femoston® conti</b> 0.5mg/2.5mg tablets; 1mg/5mg tablets (estradiol and dydrogesterone)</p> <p><u>Continuous combined (transdermal)</u></p> <p>① <b>Evorel® Conti patches</b> (estradiol 50micrograms/24hours and norethisterone 170micrograms/24hours (matrix patch))</p>

## NI Formulary: Chapter 6 Endocrine

Please refer to the full version of the Formulary for further advice and information.

Therapeutic Area	Drug choice
<b>b) Women who have had a hysterectomy or who have a Mirena® Intra Uterine System (ISU) in situ</b>	<p><u>Unopposed oestrogens (oral)</u></p> <p>① <b>Elleste-Solo®</b> 1mg, 2mg (estradiol) tablets</p> <p><u>Unopposed oestrogens (transdermal)</u></p> <p>① <b>Evorel®</b> patches 50micrograms (or 25micrograms, 75micrograms, 100micrograms/24 hours) (estradiol)</p> <p><u>Unopposed oestrogens (gel)</u></p> <p>① <b>Oestrogel®</b> 0.06% gel</p>
<b>Posterior pituitary hormones and antagonists</b> <b>(a) diabetes insipidus</b>	<p>① <b>Desmopressin</b> nasal spray 10micrograms/metered spray; intranasal solution 100micrograms/mL</p> <p>② <b>Desmopressin</b> tablets 100micrograms, 200micrograms or <b>Desmopressin</b> sublingual tablets 60 micrograms, 120 micrograms, 240 micrograms</p>
<b>(b) antidiuretic hormone antagonists</b>	<p>① <b>Demeclocycline</b> capsules 150mg Prescribe under specialist supervision</p>
<b>Drugs for the treatment and management of Osteoporosis</b> <b>(a) Calcium and Vitamin D</b>	<p>① <b>Adcal-D3®</b> Caplets 750mg/200IU</p> <p>② <b>Calceos®</b> 500mg/400IU chewable tablets</p> <p><u>Reserve (for patients who cannot swallow caplets or take chewable tablets)</u></p> <p><b>Calfovite D3®</b> 1200mg/800IU powder for oral suspension</p>
<b>(b) bisphosphonates</b>	<p>① <b>Risedronate sodium</b> tablets 35mg or <b>Alendronic acid</b> tablets 70mg</p>
<b>Treatment of hyperprolactinaemia</b>	<p>① <b>Cabergoline</b> tablets 500 micrograms</p> <p>② <b>Bromocriptine</b> tablets 1mg, 2.5mg; capsules 5mg, 10mg or <b>Quinagolide</b> tablets 25 micrograms, 50micrograms, 75micrograms</p>
<b>Acromegaly</b>	<p>The primary treatment of acromegaly is usually pituitary surgery. Management and treatment requires specialist involvement. Please refer to Prescribing Notes in full version of formulary.</p>